Literature DB >> 19574419

Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells.

Rebecca E Cagnina1, Susan I Ramos, Melissa A Marshall, Guoquan Wang, C Renea Frazier, Joel Linden.   

Abstract

The adenosine A(2B) receptor (A(2B)R) has a wide tissue distribution that includes fibroblasts and endothelial and epithelial cells. The recent generation of an A(2B)R(-/-) mouse constructed with a beta-galactosidase (beta-gal) reporter gene under control of the endogenous promoter has provided a valuable tool to quantify A(2B)R promoter activity (29). To determine the sites of expression of the A(2B) receptor in the mouse lung, histological and flow cytometric analysis of beta-gal reporter gene expression in various lung cell populations was performed. The major site of A(2B)R promoter activity was found to be the type II alveolar epithelial cells (AECs), identified by coexpression of prosurfactant protein C, with relatively less expression in alveolar macrophages, bronchial epithelial cells, and cells of the vasculature. Highly purified type II AECs were prepared by fluorescence-activated sorting of enhanced green fluorescent protein (eGFP)-positive cells from transgenic mice expressing eGFP under control of the surfactant protein C promoter (21). The type II cells expressed 89-fold higher A(2B)R mRNA than pulmonary leukocytes, and the A(2B)R was shown to be functional, as treatment of purified type II AECs with the nonspecific adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) induced an increase in intracellular cAMP greater that the beta-adrenergic agonist isoproterenol that was inhibited completely following treatment by ATL-802, a novel, highly potent (K(i) = 8.6 nM), and selective (>900 fold over other adenosine receptor subtypes) antagonist of the mouse A(2B)R.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574419      PMCID: PMC2739776          DOI: 10.1152/ajplung.90553.2008

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  31 in total

1.  A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice.

Authors:  Tobias Eckle; Almut Grenz; Stefanie Laucher; Holger K Eltzschig
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

2.  Regulation of SP-B and SP-C secretion in rat type II cells in primary culture.

Authors:  L I Gobran; S A Rooney
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-12       Impact factor: 5.464

3.  Compartmentalized autocrine signaling to cystic fibrosis transmembrane conductance regulator at the apical membrane of airway epithelial cells.

Authors:  P Huang; E R Lazarowski; R Tarran; S L Milgram; R C Boucher; M J Stutts
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

4.  A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells.

Authors:  Hongyan Zhong; Luiz Belardinelli; Tenning Maa; Igor Feoktistov; Italo Biaggioni; Dewan Zeng
Journal:  Am J Respir Cell Mol Biol       Date:  2003-07-10       Impact factor: 6.914

5.  Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway.

Authors:  Michael R Blackburn; Chun G Lee; Hays W J Young; Zhou Zhu; Janci L Chunn; Min Jong Kang; Suman K Banerjee; Jack A Elias
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

6.  Identification and isolation of mouse type II cells on the basis of intrinsic expression of enhanced green fluorescent protein.

Authors:  Jason M Roper; Rhonda J Staversky; Jacob N Finkelstein; Peter C Keng; Michael A O'Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-05-09       Impact factor: 5.464

7.  CXC chemokines and their receptors are expressed in type II cells and upregulated following lung injury.

Authors:  Jeff N Vanderbilt; Edward M Mager; Lennell Allen; Teiji Sawa; Jeanine Wiener-Kronish; Robert Gonzalez; Leland G Dobbs
Journal:  Am J Respir Cell Mol Biol       Date:  2003-06-26       Impact factor: 6.914

8.  Expression of functional toll-like receptor-2 and -4 on alveolar epithelial cells.

Authors:  Lynne Armstrong; Andrew R L Medford; Kay M Uppington; John Robertson; Ian R Witherden; Teresa D Tetley; Ann B Millar
Journal:  Am J Respir Cell Mol Biol       Date:  2004-03-25       Impact factor: 6.914

Review 9.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

10.  Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors.

Authors:  Y C Kim; X Ji; N Melman; J Linden; K A Jacobson
Journal:  J Med Chem       Date:  2000-03-23       Impact factor: 8.039

View more
  19 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

2.  Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury.

Authors:  Ulrich Schingnitz; Katherine Hartmann; Christopher F Macmanus; Tobias Eckle; Stephanie Zug; Sean P Colgan; Holger K Eltzschig
Journal:  J Immunol       Date:  2010-03-26       Impact factor: 5.422

3.  Lung injury pathways: Adenosine receptor 2B signaling limits development of ischemic bronchiolitis obliterans organizing pneumonia.

Authors:  John C Densmore; Terry R Schaid; Paul M Jeziorczak; Meetha Medhora; Said Audi; Shraddha Nayak; John Auchampach; Melinda R Dwinell; Aron M Geurts; Elizabeth R Jacobs
Journal:  Exp Lung Res       Date:  2017-03-07       Impact factor: 2.459

4.  An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering.

Authors:  Elizabeth Ntantie; Patrick Gonyo; Ellen L Lorimer; Andrew D Hauser; Nathan Schuld; Donna McAllister; Balaraman Kalyanaraman; Michael B Dwinell; John A Auchampach; Carol L Williams
Journal:  Sci Signal       Date:  2013-05-28       Impact factor: 8.192

Review 5.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

6.  Alveolar Epithelial A2B Adenosine Receptors in Pulmonary Protection during Acute Lung Injury.

Authors:  Sandra Hoegl; Kelley S Brodsky; Michael R Blackburn; Harry Karmouty-Quintana; Bernhard Zwissler; Holger K Eltzschig
Journal:  J Immunol       Date:  2015-07-17       Impact factor: 5.422

7.  Attenuation of Pulmonary Ischemia-Reperfusion Injury by Adenosine A2B Receptor Antagonism.

Authors:  Mary E Huerter; Ashish K Sharma; Yunge Zhao; Eric J Charles; Irving L Kron; Victor E Laubach
Journal:  Ann Thorac Surg       Date:  2016-04-22       Impact factor: 4.330

8.  Lungs donated after circulatory death and prolonged warm ischemia are transplanted successfully after enhanced ex vivo lung perfusion using adenosine A2B receptor antagonism.

Authors:  Eric J Charles; J Hunter Mehaffey; Ashish K Sharma; Yunge Zhao; Mark H Stoler; James M Isbell; Christine L Lau; Curtis G Tribble; Victor E Laubach; Irving L Kron
Journal:  J Thorac Cardiovasc Surg       Date:  2017-04-12       Impact factor: 5.209

9.  Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury.

Authors:  Leo M Gazoni; Dustin M Walters; Eric B Unger; Joel Linden; Irving L Kron; Victor E Laubach
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-15       Impact factor: 5.209

10.  Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury.

Authors:  Tobias Eckle; Kelly Hughes; Heidi Ehrentraut; Kelley S Brodsky; Peter Rosenberger; Doo-Sup Choi; Katya Ravid; Tingting Weng; Yang Xia; Michael R Blackburn; Holger K Eltzschig
Journal:  FASEB J       Date:  2013-04-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.